GO:0002503 peptide antigen assembly with MHC class II protein complex: Antigen Presentation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002503 describes the binding of a peptide to the antigen binding groove of an MHC class II protein complex, a critical step in adaptive immunity.
• This process occurs primarily in professional antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages, within specialized endosomal compartments.
• The invariant chain (CD74) and HLA-DM are key regulators that control peptide loading and exchange onto MHC class II molecules.
• Dysregulation of peptide antigen assembly with MHC class II is linked to autoimmune diseases, immunodeficiencies, and cancer immune evasion.
• CRISPR-based knockout, knock-in, and point mutation models enable precise dissection of genes involved in this pathway.
• Understanding this process informs vaccine design, immunotherapy, and drug development targeting antigen presentation.
Description
The term GO:0002503, peptide antigen assembly with MHC class II protein complex, refers to the binding of a peptide to the antigen binding groove of an MHC class II protein complex. This biological process is a cornerstone of adaptive immunity, enabling CD4+ T cells to recognize extracellular pathogens and initiate appropriate immune responses. The assembly occurs in specialized endosomal compartments of professional antigen-presenting cells, where MHC class II molecules are loaded with peptides derived from endocytosed antigens. The precise regulation of this process ensures that only high-affinity peptides are presented, preventing autoimmunity while maintaining effective pathogen surveillance. Researchers study GO:0002503 to understand immune recognition, develop vaccines, and design therapies for autoimmune diseases and cancer.
peptide antigen assembly with MHC class II protein complex At A Glance
| GO ID | GO:0002503 |
|---|---|
| GO term | peptide antigen assembly with MHC class II protein complex |
| Ontology | biological_process |
| Synonym | None |
| Major function | Binding of peptide to MHC class II antigen binding groove |
| Cellular location | Endosomal compartments (MIIC) of antigen-presenting cells |
| Key molecules | MHC class II (HLA-DR, HLA-DP, HLA-DQ), invariant chain (CD74), HLA-DM, HLA-DO |
| Related processes | Antigen processing and presentation, endocytosis, vesicular trafficking |
What Is GO:0002503?
In our own words, GO:0002503 encompasses the molecular event where a peptide fragment binds to the groove of an MHC class II heterodimer (typically an alpha and beta chain), forming a stable peptide-MHC class II complex. This step is essential for presenting extracellular antigens to CD4+ T lymphocytes. The process is facilitated by chaperones and accessory molecules that ensure proper peptide selection and loading.
Why Is peptide antigen assembly with MHC class II protein complex Important in Cell Biology?
GO:0002503 is fundamental to adaptive immunity because it determines which peptides are displayed to CD4+ T cells, thereby shaping immune responses against pathogens and tumors. Defects in this process can lead to immunodeficiency or autoimmunity, and its manipulation is central to vaccine development and cancer immunotherapy.
• Enables CD4+ T cell activation and coordination of immune responses.
• Critical for host defense against extracellular pathogens.
• Dysregulation is associated with autoimmune diseases such as rheumatoid arthritis and lupus.
• Plays a role in tumor immune surveillance and evasion.
• Target for therapeutic intervention in autoimmune disorders and cancer.
• Informs vaccine design by optimizing peptide-MHC class II presentation.
• Essential for understanding mechanisms of immunomodulatory drugs like hydroxychloroquine.
• Provides a model for studying endosomal trafficking and protein assembly.
• Relevant to transplantation immunology and graft rejection.
• Key to developing personalized immunotherapies.
What Happens During peptide antigen assembly with MHC class II protein complex?
MHC Class II Synthesis and Invariant Chain Association
In simple terms: Newly made MHC class II proteins pair with a chaperone called invariant chain to travel safely to endosomes.
MHC class II alpha and beta chains are synthesized in the endoplasmic reticulum (ER), where they associate with the invariant chain (CD74). The invariant chain blocks the peptide-binding groove, preventing premature binding of ER peptides, and directs the complex to endosomal compartments. This step is crucial for proper folding and trafficking of MHC class II molecules.
Antigen Processing and Peptide Generation
In simple terms: Extracellular proteins are taken up by the cell and chopped into small peptides inside endosomes.
Antigens internalized via endocytosis or phagocytosis are degraded by proteases (e.g., cathepsins) in increasingly acidic endosomal compartments. This generates peptide fragments of appropriate length (typically 13-25 amino acids) for MHC class II binding. The invariant chain is progressively cleaved, leaving a class II-associated invariant chain peptide (CLIP) in the groove.
Peptide Loading and Exchange
In simple terms: A helper molecule called HLA-DM swaps the placeholder peptide for a real antigen peptide.
In the MHC class II compartment (MIIC), HLA-DM catalyzes the removal of CLIP and facilitates the binding of high-affinity antigenic peptides to the MHC class II groove. This peptide exchange is a key regulatory step that ensures presentation of diverse peptides. HLA-DO can modulate HLA-DM activity in B cells and thymic epithelium.
Stabilization and Surface Presentation
In simple terms: The stable peptide-MHC complex moves to the cell surface to show the peptide to T cells.
Once a stable peptide-MHC class II complex is formed, it is transported to the plasma membrane via vesicular trafficking. The complex is then presented to CD4+ T cells, which recognize the peptide-MHC combination through their T cell receptors. This interaction initiates downstream signaling and adaptive immune responses.
Key Genes Involved in GO:0002503 peptide antigen assembly with MHC class II protein complex
The following genes and proteins are central to the process of peptide antigen assembly with MHC class II protein complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-DRA | MHC class II alpha chain | Forms heterodimer with beta chain; peptide binding groove |
| HLA-DRB1 | MHC class II beta chain | Polymorphic; determines peptide binding specificity |
| CD74 | Invariant chain | Chaperone blocking groove; trafficking |
| HLA-DMA | HLA-DM alpha chain | Catalyzes peptide exchange |
| HLA-DMB | HLA-DM beta chain | Catalyzes peptide exchange |
| HLA-DOA | HLA-DO alpha chain | Modulates HLA-DM function |
| HLA-DOB | HLA-DO beta chain | Modulates HLA-DM function |
| CTSB | Cathepsin B | Proteolytic processing of antigens |
| CTSD | Cathepsin D | Proteolytic processing of antigens |
| CTSL | Cathepsin L | Proteolytic processing of invariant chain |
| LAMP1 | Lysosomal-associated membrane protein 1 | Marker of MIIC; vesicle trafficking |
| LAMP2 | Lysosomal-associated membrane protein 2 | Marker of MIIC; vesicle trafficking |
| RAB7A | Rab7a GTPase | Endosomal trafficking |
| VAMP7 | Vesicle-associated membrane protein 7 | Vesicle fusion |
| AP1M1 | AP-1 complex subunit mu-1 | Sorting of MHC class II |
| BLOC1S1 | Biogenesis of lysosome-related organelles complex 1 | MIIC formation |
| TAP1 | Transporter 1, ATP binding cassette | Peptide transport (cross-talk) |
How Is peptide antigen assembly with MHC class II protein complex Regulated?
The process of peptide antigen assembly with MHC class II is regulated at multiple levels. The invariant chain (CD74) controls trafficking and protects the groove. HLA-DM and HLA-DO modulate peptide exchange, with HLA-DO inhibiting HLA-DM in a pH-dependent manner. Inflammatory cytokines such as IFN-gamma upregulate MHC class II expression and components of the antigen processing machinery. Additionally, the endosomal environment, including pH and protease activity, influences peptide generation and loading.
peptide antigen assembly with MHC class II protein complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-DRB1 | Rheumatoid arthritis, lupus | Knock-in of risk alleles in cell lines |
| CD74 | Cancer progression, metastasis | Knockout in tumor cell lines |
| HLA-DMA | Bare lymphocyte syndrome | Point mutation to abrogate catalytic activity |
| CTSL | Autoimmunity, antigen processing defects | Knockout in dendritic cells |
| HLA-DOA | Modulation of antigen presentation | Overexpression in B cells |
Autoimmune Diseases
Aberrant peptide antigen assembly with MHC class II can lead to presentation of self-peptides, triggering autoimmune responses. For example, hydroxychloroquine, used to treat rheumatoid arthritis and lupus, raises endosomal pH and interferes with antigen processing, thereby reducing MHC class II presentation. Polymorphisms in HLA-DR and HLA-DQ genes are strongly associated with autoimmune conditions.
Cancer
Tumor cells can evade immune detection by downregulating MHC class II or altering the peptide repertoire presented. CD74 (invariant chain) is overexpressed in several cancers and promotes tumor progression and metastasis. Understanding peptide loading in cancer may inform immunotherapies that enhance tumor antigen presentation.
Immunodeficiencies
Defects in genes involved in MHC class II assembly, such as HLA-DM or invariant chain, can cause bare lymphocyte syndrome, a severe immunodeficiency characterized by lack of MHC class II expression and impaired CD4+ T cell responses.
From peptide antigen assembly with MHC class II protein complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of CD74 affect peptide loading? | CD74 knockout in HeLa or HEK293T cells |
| What is the effect of HLA-DM point mutation on peptide exchange? | HLA-DMA point mutation (e.g., catalytic dead) in B cell lines |
| Can a specific HLA-DR allele present a neo-antigen? | Knock-in of HLA-DRB1*04:01 into MHC-II-negative cells |
| How does overexpression of HLA-DO modulate antigen presentation? | Overexpression of HLA-DO in B cells |
| What is the role of cathepsin L in invariant chain processing? | CTSL knockout in primary dendritic cells |
| Does tagged HLA-DR allow tracking of peptide loading? | Tagged knock-in of HLA-DRA with GFP in APCs |
How to Study the peptide antigen assembly with MHC class II protein complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface peptide-MHC class II levels | Quantify presentation after gene knockout |
| Immunopeptidomics | Peptide sequences bound to MHC class II | Identify antigenic peptides and changes in repertoire |
| FRET peptide binding assay | Real-time peptide exchange kinetics | Assess HLA-DM catalytic activity |
| Confocal microscopy | Co-localization of MHC class II with endosomal markers | Study trafficking and MIIC formation |
| CRISPR knockout screen | Genes affecting MHC class II presentation | Discover novel regulators |
| Western blot | Protein expression of MHC class II, CD74, HLA-DM | Validate knockout efficiency |
| qPCR | mRNA levels of antigen processing genes | Measure transcriptional regulation |
Flow Cytometry and Immunofluorescence
Flow cytometry using antibodies against peptide-MHC class II complexes (e.g., specific for CLIP or antigenic peptides) allows quantification of surface presentation. Immunofluorescence microscopy can visualize co-localization of MHC class II with endosomal markers like LAMP1.
Mass Spectrometry-Based Immunopeptidomics
Immunoprecipitation of MHC class II complexes followed by mass spectrometry identifies the repertoire of bound peptides, revealing how genetic or pharmacological perturbations alter peptide loading.
Biochemical Peptide Binding Assays
In vitro peptide binding assays using purified MHC class II and fluorescently labeled peptides measure binding affinity and kinetics, and can assess the impact of mutations in HLA-DM or invariant chain.
CRISPR Screens
Genome-wide CRISPR knockout screens coupled with readouts of MHC class II surface expression or peptide presentation can identify novel regulators of GO:0002503.
How CRISPR Can Be Used to Study GO:0002503 peptide antigen assembly with MHC class II protein complex
Knockout
CRISPR knockout of genes such as CD74, HLA-DMA, or CTSL in antigen-presenting cell lines (e.g., HeLa, HEK293T, or primary dendritic cells) can abolish or impair peptide antigen assembly with MHC class II, providing causal evidence for their roles. Knockout models are essential for dissecting the contribution of individual proteases and chaperones.
Point Mutation
Introducing point mutations in HLA-DMA (e.g., catalytic dead) or in the MHC class II peptide-binding groove can reveal specific residues required for peptide exchange or binding. Such models help distinguish between structural and catalytic functions.
Knock-in
Knock-in of specific HLA-DR or HLA-DQ alleles into MHC class II-negative cells allows study of allele-specific peptide presentation and disease association. Tagged knock-in (e.g., HLA-DRA-GFP) enables tracking of MHC class II trafficking and loading in live cells.
Overexpression
Overexpression of HLA-DO or invariant chain (CD74) can modulate peptide loading and presentation, mimicking pathological states such as cancer. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports peptide antigen assembly with MHC class II protein complex Research
Researchers studying peptide antigen assembly with MHC class II protein complex-related genes often need to determine whether a candidate gene is causally involved in peptide loading, presentation, or immune regulation. EDITGENE provides tailored CRISPR solutions to generate precise cellular models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for peptide antigen assembly with MHC class II protein complex research.
Frequently Asked Questions About peptide antigen assembly with MHC class II protein complex
What is GO:0002503?
GO:0002503 is the Gene Ontology term for the binding of a peptide to the antigen binding groove of an MHC class II protein complex, a key step in antigen presentation.
What genes are involved in peptide antigen assembly with MHC class II?
Key genes include HLA-DRA, HLA-DRB1, CD74, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, CTSB, CTSD, CTSL, and LAMP1.
Where does peptide antigen assembly with MHC class II occur?
It occurs in endosomal compartments, specifically the MHC class II compartment (MIIC), of professional antigen-presenting cells.
What is the role of the invariant chain in this process?
The invariant chain (CD74) binds MHC class II in the ER, blocks the peptide groove, and directs trafficking to endosomes.
How is peptide exchange catalyzed?
HLA-DM catalyzes the removal of CLIP and facilitates binding of high-affinity peptides to MHC class II.
What diseases are associated with defects in this process?
Defects can cause bare lymphocyte syndrome, autoimmune diseases like rheumatoid arthritis, and cancer immune evasion.
How can CRISPR be used to study peptide antigen assembly?
CRISPR knockout, knock-in, and point mutation models allow precise manipulation of genes like CD74 or HLA-DMA to study their roles.
What methods are used to study peptide-MHC class II assembly?
Flow cytometry, immunopeptidomics, FRET binding assays, and microscopy are commonly used.
What is CLIP?
CLIP is the class II-associated invariant chain peptide that occupies the MHC class II groove until exchanged for antigenic peptides.
Why is this process important for immunotherapy?
Understanding peptide loading informs vaccine design and cancer immunotherapy by optimizing antigen presentation.
Conclusion
GO:0002503, peptide antigen assembly with MHC class II protein complex, is a central event in adaptive immunity that determines which peptides are presented to CD4+ T cells. Its precise regulation involves a network of chaperones, proteases, and catalytic molecules such as the invariant chain and HLA-DM. Dysregulation of this process contributes to autoimmunity, immunodeficiency, and cancer, making it a prime target for therapeutic intervention. Advances in CRISPR-based models and immunopeptidomics continue to unravel the molecular details of this pathway, offering new opportunities for drug and vaccine development.
References
- 1. Blum JS et al.. 2013. Pathways of antigen processing.. Annu Rev Immunol 31:443-73 PMID: 23298205
- 2. Fox RI. 1993. Mechanism of action of hydroxychloroquine as an antirheumatic drug.. Semin Arthritis Rheum 23(2 Suppl 1):82-91 PMID: 8278823
- 4. Wang N et al.. 2024. Structural insights into human MHC-II association with invariant chain.. Proc Natl Acad Sci U S A 121(19):e2403031121 PMID: 38687785
- 5. Bryant P et al.. 2004. Class II MHC peptide loading by the professionals.. Curr Opin Immunol 16(1):96-102 PMID: 14734116
- 7. Bandola-Simon J et al.. 2026. MHC Class II and Beyond: Complex Role of CD74 in Cancer.. Cells 15(2) PMID: 41597203
- 8. Jensen PE et al.. 1999. Peptide exchange in MHC molecules.. Immunol Rev 172:229-38 PMID: 10631949
